The sand­box: Park­er In­sti­tute throws its re­search mus­cle be­hind gene ther­a­py tech for de­stroy­ing can­cer cells

John Bea­dle

John Bea­dle and the big re­search team at PsiOxus have thought a lot about in­fil­trat­ing the ranks of can­cer cells, to go in­side cells to cause their self-de­struc­tion with one of the in­dus­try’s lead­ing “un­armed” on­colytc virus pro­grams. But they’re al­so go­ing one big step fur­ther, us­ing their gene ther­a­py tech to pen­e­trate these cells to de­liv­er weapons for their mass de­struc­tion. And they’re lin­ing up some pow­er­house al­lies at the Park­er In­sti­tute for Can­cer Im­munother­a­py to speed the work.

What’s the big idea?

PsiOxus — with 95 most­ly re­search staffers in Ox­ford and Philadel­phia — gained con­sid­er­able at­ten­tion for its sys­temic ap­proach to de­liv­er­ing on­colyt­ic virus­es, in­fect­ing cells that would then burst, at­tract­ing T cells in­to the tu­mor. But there are al­so scores of on­colyt­ic virus­es in the pipeline. In this case they’re work­ing a re­verse strat­e­gy to CAR-T. In­stead of mod­i­fy­ing the T cell to go af­ter can­cer cells, they’re mod­i­fy­ing the can­cer cells to get them to en­gage with T cells — en­gi­neer­ing the can­cer cell to ex­press T cell en­gag­ing lig­ands.

The ques­tion has been what genes should be added to do the best job. And they be­lieve the IV ap­proach — steer­ing clear of in­tra­tu­moral in­jec­tions — should help sim­pli­fy things con­sid­er­ably, up­ping their chances of suc­cess in hit­ting the tar­get.

PsiOxus al­ready gained the sup­port of Bris­tol-My­ers Squibb, which part­nered on the biotech’s NG-348 in a $915 mil­lion deal in late 2016. That drug en­codes two im­munomod­u­la­to­ry MiTe pro­teins in its genome: a hu­man CD80 and an an­ti­body frag­ment spe­cif­ic for the T-cell re­cep­tor CD3 pro­tein, both de­signed to muster T cells to at­tack spe­cif­ic can­cer cells on­ly.

Saman­tha Buck­trout

“They’re such a great group,” says Park­er In­sti­tute Di­rec­tor of Re­search Saman­tha Buck­trout about PsiOxus. “When we go to have dis­cus­sions, it’s a ‘no-idea-is-stu­pid’ zone, but al­so an ego-free zone. They’ve done a lot of rig­or­ous work to move their pipeline for­ward, both pre-clin­i­cal and in the clin­ic, and aren’t afraid to take risks. We see a lot of blue sky in terms of where we can go with them, sci­en­tif­i­cal­ly.”

Those blue skies are what spurred tech mogul Sean Park­er to set up his epony­mous in­sti­tute, or­ga­niz­ing a net­work of more than 300 promi­nent sci­en­tists with fi­nan­cial sup­port and cre­at­ing net­works of ex­perts to as­sist the com­pa­nies they work with to dig deep­er and go be­yond the fron­tiers of com­mer­cial I/O. But they’re al­so goal ori­ent­ed, pur­su­ing what PI­CI chief Jeff Blue­stone calls a “sand­box” strat­e­gy: a con­tained, or­ga­nized ap­proach to their work dri­ven by a set of clear ob­jec­tives.

Ex­tra fund­ing is al­ways good, says Bea­dle, but it’s the peo­ple Park­er brings to the ta­ble that make the big dif­fer­ence.

“The key is their net­work of in­sti­tu­tions and aca­d­e­mics,” notes the CEO, who ex­pects to even­tu­al­ly put to­geth­er an­oth­er round for the biotech be­fore even­tu­al­ly set­ting their sights on an IPO.

The plan at PsiOxus is to move two pro­grams in­to the clin­ic, with an IND com­ing in Q1 of next year. The first is a CD40 ag­o­nist, and the sec­ond will in­clude a pack­age of 4 dif­fer­ent genes cov­er­ing a bis­pe­cif­ic with chemokines to at­tract T cells and an­oth­er to ex­press in­ter­fer­on al­pha to ac­ti­vate den­drit­ic cells.

Health­care Dis­par­i­ties and Sick­le Cell Dis­ease

In the complicated U.S. healthcare system, navigating a serious illness such as cancer or heart disease can be remarkably challenging for patients and caregivers. When that illness is classified as a rare disease, those challenges can become even more acute. And when that rare disease occurs in a population that experiences health disparities, such as people with sickle cell disease (SCD) who are primarily Black and Latino, challenges can become almost insurmountable.

Jacob Van Naarden (Eli Lilly)

Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer biotech buy­out

It’s taken 7 years, but Eli Lilly is promising to finally start hammering the small and affluent PD-(L)1 club with a “disruptive” pricing strategy for their checkpoint therapy allied with China’s Innovent.

Lilly in-licensed global rights to sintilimab a year ago, building on the China alliance they have with Innovent. That cost the pharma giant $200 million in cash upfront, which they plan to capitalize on now with a long-awaited plan to bust up the high-price market in lung cancer and other cancers that have created a market worth tens of billions of dollars.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

The End­points 11: They've got mad mon­ey and huge am­bi­tions. It's time to go big or go home

These days, selecting a group of private biotechs for the Endpoints 11 spotlight begins with a sprint to get ahead of IPOs and the M&A teams at Big Pharma. I’ve had a couple of face plants earlier this year, watching some of the biotechs on my short list choose a quick leap onto Nasdaq or into the arms of a buyer.

Vividion, you would have been a great pick for the Endpoints 11. I’m sorry I missed you.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Dave Lennon, former president of Novartis Gene Therapies

So what hap­pened with No­var­tis Gene Ther­a­pies? Here's your an­swer

Over the last couple of days it’s become clear that the gene therapy division at Novartis has quietly undergone a major reorganization. We learned on Monday that Dave Lennon, who had pursued a high-profile role as president of the unit with 1,500 people, had left the pharma giant to take over as CEO of a startup.

Like a lot of the majors, Novartis is an open highway for head hunters, or anyone looking to staff a startup. So that was news but not completely unexpected.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

FDA+ roundup: Bs­U­FA III ready for show­time, court tells FDA to re-work com­pound­ing plan, new guid­ance up­dates and more

The FDA has now spelled out what exactly will be included in the third iteration of Biosimilar User Fee Act (BsUFA) from 2023 through 2027, which similarly to the prescription drug deal, sets fees that industry has to pay for submitting applications, in exchange for firm timelines that the agency must meet.

This latest deal includes several sweeteners for the biosimilar industry, which has yet to make great strides in the US market, with shorter review timelines for safety labeling updates and updates to add or remove an indication that does not contain efficacy data.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Who are the women su­per­charg­ing bio­phar­ma R&D? Nom­i­nate them for this year's spe­cial re­port

The biotech industry has faced repeated calls to diversify its workforce — and in the last year, those calls got a lot louder. Though women account for just under half of all biotech employees around the world, they occupy very few places in C-suites, and even fewer make it to the helm.

Some companies are listening, according to a recent BIO survey which showed that this year’s companies were 2.5 times more likely to have a diversity and inclusion program compared to last year’s sample. But we still have a long way to go. Women represent just 31% of biotech executives, BIO reported. And those numbers are even more stark for women of color.

Joshua Liang, Clover Biopharmaceuticals CEO

With world still in sore need of dos­es, Clover says its Covid-19 vac­cine is 67% ef­fec­tive in Phase III

With concerns about the Delta variant rising and much of the world still in desperate need of vaccine doses, a Chinese biotech announced Wednesday that a new shot has shown positive results in a large trial against Covid-19, including new variants.

Clover Biopharmaceuticals announced Wednesday that its vaccine candidate showed 79% efficacy against the Delta variant in a Phase II/III trial dubbed Spectra, and 67% effective against Covid-19 overall.

Jean Bennett (Brent N. Clarke/Invision/AP Images)

Lux­tur­na in­ven­tor Jean Ben­nett starts a new gene ther­a­py com­pa­ny to tack­le rare dis­eases left be­hind by phar­ma, VCs

A few years ago Jean Bennett found herself in a surprising place for a woman who invented the first gene therapy ever approved in the United States: No one, it seemed, wanted her work.

Bennett, who designed and co-developed Luxturna, approved in 2018 for a rare form of blindness, had kept building new gene therapies for eye diseases at her University of Pennsylvania lab. But although the results in animals looked promising, pharma companies and investors kept turning down the pedigreed ophthalmology professor.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,900+ biopharma pros reading Endpoints daily — and it's free.

Maureen Hillenmeyer, Hexagon Bio CEO

Hexa­gon Bio rais­es $61M to con­tin­ue ef­forts to turn fun­gi in­to drugs

A year after raising a $47 million launch round, the fungi-loving drug hunters at Hexagon Bio have more than doubled their coffers.

Hexagon announced today that it raised another $61 million for its efforts to design cancer and infectious disease drugs based on insights mined from the DNA in millions of species of fungi. The new financing brings Hexagon’s committed funding to over $108 million.